Aytu BioScience (OTC: AYTU) is a commercial-stage specialty healthcare company with a portfolio of commercial and late-stage urology products addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu currently markets ProstaScint, which is FDA-approved as an imaging agent for use in both newly diagnosed, high-risk prostate cancer patients and patients with recurrent prostate cancer; Primsol®, the only FDA-approved trimethoprim-only oral solution for urinary tract infections; and outside the U.S., the CE Marked MiOXSYS™ System. MiOXSYS is the only rapid test for assessing oxidative stress in semen and seminal plasma, a leading contributor of idiopathic male infertility. For more information, visit the company’s website at  www.aytubio.com